Radiation oncology leadership need to simultaneously advocate for payment reform but emphasize that nothing else in the oncology world is as cost effective as radiation therapy.
Our economy spends more on a single drug—-pembrolizumab—-than all radiation treatments combined.
Grateful for my work fam at @COH_RadOnc for throwing me and my wife the sweetest baby shower. Can’t ask for a better group of people to work with everyday. Expecting twin boys soon!
Physician Spotlight:
@JasonRLiuMD is a COH trained rad onc at our South Pasadena network site. His office has recently implemented prone breast radiation and has treated >30 patients with osteoarthritis with LDRT. Clinical trials are also an option with a research nurse on staff!
#astro25@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.
Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased
3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.
Goodbye WPRT
Colleagues recent experience submitting RCT to top tier journal
This is ridiculous. Does it have to be so painful?
Like everything in life, too much or too little (peer review in this case) is not good!
It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in @TheLancetOncol
Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR
⚖️ No difference in overall survival
😰 Serious adverse events 40%
👍 Both regimens may be considered
https://t.co/9nfnPUyhCR
We're proud to celebrate Robert Stone, CEO of @cityofhope, and @DrMvandenBrink, President of City of Hope Los Angeles and City of Hope National Medical Center, for being named to the @LABJnews 2025 LA500 list, honoring Los Angeles' most influential leaders. #LA500
🔥NSABP- B51 is out!
Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer
👉longer follow up desired
👉applicability across subtypes?
👉Impact of more modern systemic therapies ?
@NRGonc@ASTRO_org#BreastCancer
https://t.co/ISD7HOd5q7
🚨 Wow! #ASCO25@ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert
This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
❗️ Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer (ACHILES)
HR 1.14 (0.76-1.71)
👎 and makes me wonder re: ADRIATIC as well 🤔 #ASCO25
We are excited to announce Dr. Scott Glaser in his new role as Residency Program Director. He is an excellent teacher, mentor, and incredibly committed to resident education. Congratulations on your new appointment.